Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (64)

I-01Andrijana Radivojevic

Enhancing population PK modeling efficiency using an integrated workflow

Wednesday 10:05-11:40

I-02Gauri Rao

A Proposed Adaptive Feedback Control (AFC) Algorithm for Linezolid (L) based on Population Pharmacokinetics (PK)/Pharmacodynamics (PD)/Toxicodynamics(TD)

Wednesday 10:05-11:40

I-03Sylvie Retout

A drug development tool for trial simulation in prodromal Alzheimer’s patient using the Clinical Dementia Rating scale Sum of Boxes score (CDR-SOB).

Wednesday 10:05-11:40

I-04

Constructing the disease trajectory of CDR-SOB in Alzheimer’s disease progression modelling

Wednesday 10:05-11:40

I-05Rachel Rose

Application of a Physiologically Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model to Investigate the Effect of OATP1B1 Genotypes on the Cholesterol Synthesis Inhibitory Effect of Rosuvastatin

Wednesday 10:05-11:40

I-06Elisabeth Rouits

Population pharmacokinetic model for Debio 1143, a novel antagonist of IAPs in cancer treatment

Wednesday 10:05-11:40

I-07Alberto Russu

Second-order indirect response modelling of complex biomarker dynamics

Wednesday 10:05-11:40

I-08Teijo Saari

Pharmacokinetics of free hydromorphone concentrations in patients after cardiac surgery

Wednesday 10:05-11:40

I-09Tarjinder Sahota

Real data comparisons of NONMEM 7.2 estimation methods with parallel processing on target-mediated drug disposition models

Wednesday 10:05-11:40

I-10Maria Luisa Sardu

Tumour Growth Inhibition In Preclinical Animal Studies: Steady-State Analysis Of Biomarker-Driven Models.

Wednesday 10:05-11:40

I-11Emilie Schindler

PKPD-Modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size following axitinib treatment in metastatic renal cell carcinoma (mRCC) patients

Wednesday 10:05-11:40

I-12

Population pharmacokinetic of rifampicine in Malawian children.

Wednesday 10:05-11:40

I-13Henning Schmidt

The “SBPOP Package”: Efficient Support for Model Based Drug Development – From Mechanistic Models to Complex Trial Simulation

Wednesday 10:05-11:40

I-14Stephan Schmidt

Mechanistic Prediction of Acetaminophen Metabolism and Pharmacokinetics in Children using a Physiologically-Based Pharmacokinetic (PBPK) Modeling Approach

Wednesday 10:05-11:40

I-15Rik Schoemaker

Scaling brivaracetam pharmacokinetic parameters from adult to pediatric epilepsy patients

Wednesday 10:05-11:40

I-16Seonghae Yoon

Population pharmacokinetic analysis of two different formulations of tacrolimus in stable pediatric kidney transplant recipients

Wednesday 10:05-11:40

I-17Catherine Sherwin

Dense Data – Methods to Handle Massive Data Sets without Compromise

Wednesday 10:05-11:40

I-18Giovanni Smania

Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation

Wednesday 10:05-11:40

I-19Alexander Solms

Translating physiologically based Parameterization and Inter-Individual Variability into the Analysis of Population Pharmacokinetics

Wednesday 10:05-11:40

I-20

A conditional repeated time-to-event analysis of onset and retention times of sildenafil erectile response

Wednesday 10:05-11:40

I-21Heiner Speth

Referenced Visual Predictive Check (rVPC)

Wednesday 10:05-11:40

I-22

Title: Rapid Repeat Dosing of Zolpidem – Apparent Kinetic Change Between Doses

Wednesday 10:05-11:40

I-23Christine Staatz

Dosage individulisation of tacroliums in adult kidney transplant recipients

Wednesday 10:05-11:40

I-24Gabriel Stillemans

A generic population pharmacokinetic model for tacrolimus in pediatric and adult kidney and liver allograft recipients

Wednesday 10:05-11:40

I-25Elisabet Størset

Predicting tacrolimus doses early after kidney transplantation – superiority of theory based models

Wednesday 10:05-11:40

I-26

A Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data in Japanese Type 2 Diabetes Patients

Wednesday 10:05-11:40

I-27

FIM approximation, spreading of optimal sampling times and their effect on parameter bias and precision.

Wednesday 10:05-11:40

I-28Herbert Struemper

Population pharmacokinetics of belimumab in systemic lupus erythematosus: insights for monoclonal antibody covariate modeling from a large data set

Wednesday 10:05-11:40

I-29Elin Svensson

Individualization of fixed-dose combination (FDC) regimens – methodology and application to pediatric tuberculosis

Wednesday 10:05-11:40

I-30Eva Sverrisdottir

Modelling analgesia-concentration relationships for morphine to evaluate experimental pain models

Wednesday 10:05-11:40

I-31Maciej Swat

PharmML – An Exchange Standard for Models in Pharmacometrics

Wednesday 10:05-11:40

I-32Amit Taneja

From Behaviour to Target: Evaluating the putative correlation between clinical pain scales and biomarkers.

Wednesday 10:05-11:40

I-33Joel Tarning

The population pharmacokinetic and pharmacodynamic properties of intramuscular artesunate and quinine in Tanzanian children with severe falciparum malaria; implications for a practical dosing regimen.

Wednesday 10:05-11:40

I-34David Ternant

Adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis

Wednesday 10:05-11:40

I-35Adrien Tessier

High-throughput genetic screening and pharmacokinetic population modeling in drug development

Wednesday 10:05-11:40

I-36Iñaki F. Trocóniz

Modelling and simulation applied to personalised medicine

Wednesday 10:05-11:40

I-37

A mechanistic population pharmacokinetic model for simvastatin and its active metabolite simvastatin acid

Wednesday 10:05-11:40

I-38Sebastian Ueckert

AD i.d.e.a. – Alzheimer’s Disease integrated dynamic electronic assessment of Cognition

Wednesday 10:05-11:40

I-39Wanchana Ungphakorn

Development of a Physiologically Based Pharmacokinetic Model for Children with Severe Malnutrition

Wednesday 10:05-11:40

I-40Elodie Valade

Population Pharmacokinetics of Emtricitabine in HIV-1-infected Patients

Wednesday 10:05-11:40

I-41Georgia Valsami

Population exchangeability in Bayesian dose individualization of oral Busulfan

Wednesday 10:05-11:40

I-42Sven van Dijkman

Predicting antiepileptic drug concentrations for combination therapy in children with epilepsy.

Wednesday 10:05-11:40

I-43Coen van Hasselt

Design and analysis of studies investigating the pharmacokinetics of anti-cancer agents during pregnancy

Wednesday 10:05-11:40

I-44Anne van Rongen

Population pharmacokinetic model characterising the influence of circadian rhythm on the pharmacokinetics of oral and intravenous midazolam in healthy volunteers

Wednesday 10:05-11:40

I-45Marc Vandemeulebroecke

Literature databases: integrating information on diseases and their treatments.

Wednesday 10:05-11:40

I-46

A Population PK Model For Citalopram And Its Major Metabolite, N-desmethyl Citalopram, In Rats

Wednesday 10:05-11:40

I-47An Vermeulen

Population Pharmacokinetic Analysis of Canagliflozin, an Orally Active Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)

Wednesday 10:05-11:40

I-48Marie Vigan

Modelling the evolution of two biomarkers in Gaucher patients receiving enzyme replacement therapy.

Wednesday 10:05-11:40

I-49Paul Vigneaux

Extending Monolix to use models with Partial Differential Equations

Wednesday 10:05-11:40

I-50Winnie Vogt

Paediatric PBPK drug-disease modelling and simulation towards optimisation of drug therapy: an example of milrinone for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery

Wednesday 10:05-11:40

I-51Max von Kleist

Systems Pharmacology of Chain-Terminating Nucleoside Analogs

Wednesday 10:05-11:40

I-52Camille Vong

Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin.

Wednesday 10:05-11:40

I-53Katarina Vučićević

Total plasma protein and haematocrit influence on tacrolimus clearance in kidney transplant patients – population pharmacokinetic approach

Wednesday 10:05-11:40

I-54

Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and asthma patients

Wednesday 10:05-11:40

I-55

Design and analysis of randomized concentration controlled

Wednesday 10:05-11:40

I-56Franziska Weber

A linear mixed effect model describing the expression of peroxisomal ABCD transporters in CD34+ stem cell-derived immune cells of X-linked Adrenoleukodystrophy and control populations

Wednesday 10:05-11:40

I-57Sebastian Weber

PK/PD assessment of tacrolimus nephrotoxicity in liver transplantation

Wednesday 10:05-11:40

I-58Mélanie Wilbaux

A drug-independent model predicting Progression-Free Survival to support early drug development in recurrent ovarian cancer

Wednesday 10:05-11:40

I-59Dan Wright

Bayesian dose individualisation provides good control of warfarin dosing.

Wednesday 10:05-11:40

I-60Klintean Wunnapuk

Population analysis of paraquat toxicokinetics in poisoning patients

Wednesday 10:05-11:40

I-61Rujia Xie

Population PK-QT analysis across Phase I studies for a p38 mitogen activated protein kinase inhibitor – PH-797804

Wednesday 10:05-11:40

I-62Shuying Yang

First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis

Wednesday 10:05-11:40

I-63Jiansong Yang

Practical diagnostic plots in aiding model selection among the general model for target-mediated drug disposition (TMDD) and its approximations

Wednesday 10:05-11:40

I-64Rui Zhu

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

Wednesday 10:05-11:40